secwatch.observer — SEC 8-K summary
======================================

Issuer:     PepGen Inc. (PEPG)
CIK:        0001835597
Form:       8-K
Filed at:   2025-09-24T23:59:59+00:00
Accession:  0001193125-25-215435
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PepGen reports 53.7% mean splicing correction in DM1 patients at 15 mg/kg dose
------------------------------------------------------------------------------

- Mean splicing correction of 53.7% at 15 mg/kg (n=6) by 22-gene panel at Day 28; all 6 patients responded.
- PGN-EDODM1 well-tolerated; no serious treatment-related AEs, all mild/moderate, transient, resolved without intervention.
- Dose-proportional muscle concentration increase vs 5 mg/kg (12.3%) and 10 mg/kg (29.1%) cohorts.
- FREEDOM2 MAD study 5 mg/kg cohort data expected Q1 2026; 10 mg/kg cohort dosing to begin Q1 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1835597/000119312525215435/0001193125-25-215435-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1835597/000119312525215435/d67598d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-215435

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer